Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | GAA | P10253 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132123 | 1.00 | MPO (0.54) | MPOALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL1132128 | 0.84 | MAPT (0.63) | MPOALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL1132158 | 0.84 | MAPT (0.63) | MPOALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL1132357 | 0.83 | MAPT (0.47) | MPOALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL1132355 | 0.83 | MAPT (0.47) | MPOALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL1132257 | 0.80 | GAA (0.55) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL1132258 | 0.80 | GAA (0.55) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL1132833 | 0.78 | GAA (0.64) | MPOALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL1132832 | 0.78 | GAA (0.64) | MPOALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL1132103 | 0.77 | MEN1 (0.71) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512066-B2 | Enhancers of protein degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-12-06 | — | — | US | claimed |
| US-20120282629-A1 | Enhancers of Protein Degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2012-11-08 | — | — | US | claimed |
| EP-2488485-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-08-22 | — | — | EP | claimed |
| WO-2011020883-A9 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-07-12 | — | — | WO | claimed |
| WO-2011020883-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-02-24 | — | — | WO | claimed |
| EP-2287149-A1 | Enhancers of protein degradation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2011-02-23 | — | — | EP | claimed |
| US-9512066-B2 | Enhancers of protein degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20120282629-A1 | Enhancers of Protein Degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2012-11-08 | — | — | US | disclosed |
| EP-2488485-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011020883-A9 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-07-12 | — | — | WO | disclosed |
| WO-2011020883-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-02-24 | — | — | WO | disclosed |
| EP-2287149-A1 | Enhancers of protein degradation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2011-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282629-A1 | Enhancers of Protein Degradation | HTT, HYPK, TFEB | MPO 2713/4885ALDH1A1 4337/4885GAA 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.